Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.44 |
| ▸ | HTR3B | O95264 | 3/20 | 0.44 |
| ▸ | HTR3A | P46098 | 3/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3466939 | 0.99 | HSD11B1 (0.45) | HSD11B1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4295305 | 0.88 | HSD11B1 (0.45) | HSD11B1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3468056 | 0.81 | HSD11B1 (0.49) | HSD11B1 | |
| SCHEMBL3469534 | 0.75 | HSD11B1 (0.44) | HSD11B1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL3469891 | 0.74 | HSD11B1 (0.43) | HSD11B1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4297498 | 0.74 | GPR119 (0.46) | THRB | |
| SCHEMBL4290539 | 0.71 | HSD11B1 (0.43) | HSD11B1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13085385 | 0.71 | HTR2C (0.58) | HTR6HTR2A | |
| SCHEMBL4300878 | 0.70 | PROKR1 (0.46) | HSD11B1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2962518 | 0.69 | FAAH (0.53) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265600-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | HSD11B1 1704/4885HTR3E 26/4885HTR3B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.